z-logo
open-access-imgOpen Access
Telomerase Inhibition Targets Clonogenic Multiple Myeloma Cells through Telomere Length-Dependent and Independent Mechanisms
Author(s) -
Sarah Brennan,
Qiuju Wang,
Robert Tressler,
Calvin B. Harley,
Ning Go,
Ekaterina Bassett,
Carol Ann Huff,
Richard J. Jones,
William Matsui
Publication year - 2010
Publication title -
plos one
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.99
H-Index - 332
ISSN - 1932-6203
DOI - 10.1371/journal.pone.0012487
Subject(s) - homeobox protein nanog , clonogenic assay , telomerase , stem cell , sox2 , telomerase reverse transcriptase , stem cell marker , cancer stem cell , telomere , cancer research , biology , microbiology and biotechnology , cell culture , chemistry , induced pluripotent stem cell , embryonic stem cell , biochemistry , genetics , gene , dna
Plasma cells constitute the majority of tumor cells in multiple myeloma (MM) but lack the potential for sustained clonogenic growth. In contrast, clonotypic B cells can engraft and recapitulate disease in immunodeficient mice suggesting they serve as the MM cancer stem cell (CSC). These tumor initiating B cells also share functional features with normal stem cells such as drug resistance and self-renewal potential. Therefore, the cellular processes that regulate normal stem cells may serve as therapeutic targets in MM. Telomerase activity is required for the maintenance of normal adult stem cells, and we examined the activity of the telomerase inhibitor imetelstat against MM CSC. Moreover, we carried out both long and short-term inhibition studies to examine telomere length-dependent and independent activities.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom